Synlogic (NASDAQ:SYBX) Stock Price Crosses Below Fifty Day Moving Average – Here’s Why

Shares of Synlogic, Inc. (NASDAQ:SYBXGet Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.67 and traded as low as $0.6112. Synlogic shares last traded at $0.68, with a volume of 1,360 shares trading hands.

Synlogic Stock Down 0.4%

The business’s 50 day moving average is $0.67 and its two-hundred day moving average is $0.75. The firm has a market cap of $7.95 million, a P/E ratio of -2.62 and a beta of 0.56.

Hedge Funds Weigh In On Synlogic

Several hedge funds have recently modified their holdings of the company. DRW Securities LLC purchased a new position in Synlogic in the fourth quarter valued at about $27,000. Citadel Advisors LLC purchased a new stake in shares of Synlogic during the third quarter worth $49,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Synlogic by 116.7% in the fourth quarter. Renaissance Technologies LLC now owns 85,627 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 46,117 shares during the period. Institutional investors own 63.40% of the company’s stock.

About Synlogic

(Get Free Report)

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.

Recommended Stories

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.